# US 2010/0167953 A1 · Methods and apparatuses for comparative genomic microarray analysis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0167953 A1
- Document ID: US20100167953A1
- Status: Published application
- Kind: A1
- Application number: 12/720,491
- Filed: 2010-03-09
- Published: 2010-07-01
- Earliest claimed: 2007-03-30
- Inventors: Blake C. Ballif; Lisa G. Shaffer; Bassem A. Bejjani
- Web page: https://patentgrep.com/patent/US20100167953A1

## CPC

- C12Q 1/6841: In situ hybridisation
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Control nucleic acids and their method of use to simultaneously test for numerous genetic alterations that involve an unbalanced arrangement of chromosomes. One implementation increases reliability and accuracy by adding additional nucleic acid to test and/or reference samples. Clones representing segments insensitive to chromosomal rearrangements are placed in non-adjacent target areas of a microarray to avoid interfering hybridization reactions.

## Claims

### Claim 1

An array for the detection of aneuploidy that comprises a first plurality of nucleic acid segments corresponding to a first set of chromosomal loci wherein each chromosomal locus is capable of genetic alteration indicative of a copy number and a second plurality of nucleic acid segments corresponding to a second set of chromosomal loci that are not associated with the copy number being detected, wherein each of the first and second plurality of nucleic acid segments represents a portion of the base-pair sequence of a chromosomal locus; wherein each nucleic acid segment is immobilized to a discrete and known spot on a substrate surface to form an array of nucleic acids, wherein the nucleic acid segments representing chromosomal loci that are adjacent on a native chromosome are placed in non-adjacent target areas of the array.

### Claim 2 (depends on 1)

The array of claim 1 wherein the aneuploidy comprises sex chromosomes imbalances.

### Claim 3 (depends on 1)

The array of claim 1 wherein the type of aneuploidy is selected from the group consisting of Turner syndrome (45,X), Klinefelter syndrome 47,XXY, 47,XXX, 45,X/46,XY, 46,XX/(male), 46,XX/46,XY(female), 47,XYY, 46,XY/47,XYY, 45,X/46,XY (male), 46,XX/47,XX,del(Yp) (female), or 46,XX/46,XY(female).

### Claim 4 (depends on 1)

The array of claim 1 wherein the aneuploidy comprises non-sex chromosome imbalances.

### Claim 5 (depends on 1)

The array of claim 1, wherein the second plurality of nucleic acids is selected from the group consisting of telomeric, pericentromeric, and pseudoautosomal chromosomal loci.

### Claim 6 (depends on 1)

The array of claim 1 wherein the second plurality of nucleic acids is comprised of nucleic acids derived from a non-human source.

### Claim 7 (depends on 6)

The array of claim 6 wherein the non-human source is selected from the group consisting of Drosophila, yeast or E. Coli.

### Claim 8

A set of control nucleic acids for use in comparative genomic hybridization analysis wherein the nucleic acids are derived from a naturally occurring sample that comprises a known aneuploidy.

### Claim 9 (depends on 8)

A set of control nucleic acids of claim 8 wherein the known aneuploidy comprises, Turner syndrome (45,X), 47,XXX, Klinefelter syndrome 47,XXY, 45,X/46,XY, 46,XX(male), 46,XX/46,XY(female), 47,XYY, 46,XY/47,XYY, 45,X/46,XY (male), 46,XX/47,XX,del(Yp) (female), or 46,XX/46,XY(female).

### Claim 10 (depends on 8)

A set of control nucleic acids of claim 8 wherein the known aneuploidy is Turner syndrome (45,X).

### Claim 11

A set of control nucleic acids for use in comparative genomic hybridization analysis wherein the nucleic acids are comprised of a mixture of known amounts of cloned nucleic acid segments corresponding to a plurality of chromosomal loci derived from a biological sample.

### Claim 12 (depends on 11)

A set of control nucleic acids of claim 11 wherein the biological sample is human.

### Claim 13 (depends on 11)

A set of control nucleic acids of claim 11 wherein the biological sample is non-human.

### Claim 14 (depends on 13)

A set of control nucleic acids of claim 13 wherein the biological sample is derived from the group of Drosophila, yeast, and E. Coli.

### Claim 15

A set of control nucleic acids for use in comparative genomic hybridization analysis that comprises a first group of a known amount of nucleic acid segments added to a test sample and a second group of a known amount of substantially identical nucleic acid segments added to a reference sample.

### Claim 16 (depends on 15)

A set of control nucleic acids of claim 15 wherein the first and second nucleic acid segments are human.

### Claim 17 (depends on 15)

A set of control nucleic acids of claim 15 wherein the first and second nucleic acid segments are non-human.

### Claim 18 (depends on 17)

A set of control nucleic acids of claim 17 wherein the non-human nucleic acid segments are derived from the group of Drosophila, yeast, and E. Coli.

### Claim 19

A method of comparative genomic hybridization analysis that comprises the following steps: (a) providing an array comprising a plurality of nucleic acid target elements, wherein each nucleic acid target element is comprised of a nucleic acid segment that is immobilized to a discrete and known spot on a substrate surface to form an array and the nucleic acid segments comprise a substantially complete first genome of a known mammalian karyotype; (b) providing a first sample, wherein the sample comprises a plurality of genomic nucleic acid segments comprising a substantially complete complement of a first genome labeled with a first detectable label; (c) providing a second sample, wherein the sample comprises a plurality of genomic nucleic acid labeled with a second detectable label, and the genomic nucleic acid sample comprises a substantially complete complement of genomic nucleic acid of a cell or a tissue sample, and the karyotype of the second sample comprises a known abnormal karyotype; (d) contacting the samples with the array of step (a) under conditions wherein the nucleic acid in the samples can specifically hybridize to the genomic nucleic acid segments immobilized on the array; (e) measuring the amount of first and second detectable label on each spot after the contacting of step (d) and determining the karyotype of the first sample by comparative genomic hybridization.

### Claim 20 (depends on 19)

The method as recited in claim 19 wherein the karyotype of the second sample comprises a known aneuploidy.

### Claim 21 (depends on 20)

The method as recited in claim 20 wherein the aneuploidies includes any of selected from the group comprising, Turner syndrome (45,X), Klinefelter syndrome 47,XXY, 47,XXX, 45,X/46,XY, 46,XX(male), 46,XX/46,XY(female), 47,XYY, 46,XY/47,XYY, 45,X/46,XY (male), 47,XXY male, 46,XX/47,XX,del(Yp) (female), or 46,XX/46,XY(female).

### Claim 22 (depends on 20)

The method of claim 20 wherein the known aneuploidy is 47,XXY.

### Claim 23 (depends on 19)

The method of claim 19 wherein the array comprises additional nucleic acid target elements derived from a non-mammalian source.

### Claim 24 (depends on 23)

The method of claim 23 wherein the non-mammalian source is from the group of Drosophila, yeast, and E. Coli.

### Claim 25 (depends on 19)

The method of claim 19 wherein the second sample additionally comprises a known amount of nucleic acid from a separate source.

### Claim 26 (depends on 25)

The method of claim 25 wherein the separate source is non-mammalian.

### Claim 27 (depends on 26)

The method of claim 26 wherein the non-mammalian source is from the group of Drosophila, yeast, and E. Coli.

### Claim 28 (depends on 19)

The method of claim 19 wherein the first and second sample additionally comprise a known amount of nucleic acid from a separate source.

### Claim 29 (depends on 28)

The method of claim 28 wherein separate source is non-mammalian.

### Claim 30 (depends on 29)

The method of claim 29 wherein the non-mammalian source is from the group of Drosophila, yeast, and E. Coli.

### Claim 31 (depends on 26)

The method of claim 26 wherein the known amount of additional nucleic acid generates a standard curve of ratios in a comparative hybridization experiment.

### Claim 32 (depends on 19)

The method as recited in claim 19 wherein the first and second detectable labels comprise fluorescent labels.
